Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033
Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial ( NCT06128382 ) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate.
- Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that the first participant has been vaccinated in its new Phase 1 trial ( NCT06128382 ) evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate.
- In a rabbit toxicology study, the vaccine candidate also showed an excellent safety and tolerance profile after intramuscular administration.
- One single dose of OVX033 vaccine or of placebo will be administered intramuscularly in 48 healthy subjects aged 18-49 years.
- OVX033 is based on Osivax’ cutting-edge technology, OligoDOMTM, which has already established promising proof-of-concept data with OVX836, a broad-spectrum influenza A vaccine candidate currently being evaluated in several Phase 2 clinical studies.